Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The webinar entitled “COVID Without Borders-A collaboration to Investigate A New Disease III – Diagnostic and Treatment for COVID-19” was held online on the morning of November 17th 2020, jointly organized by Chinese Academy of Medical Sciences (CAMS) and CAMS-Oxford Institute (COI).

On behalf of COI, Professor Tao Dong hosted this webinar and introduced two distinguished guests, Professor Chengyu Jiang and Professor Alain Townsend. 

The first speaker was Professor Chengyu Jiang from Chinese Academy of Medical Sciences, who is Deputy Director of Institute of Basic Medicine and Professor of Peking Union Medical College. She reported on her work entitled “Repurposing Drugs and Traditional Chinese Medicine—Treatments for COVID-19”. In her talk, she introduced the methodology of drug repurposing, the recommended repurposing drugs based on the role of renin angiotensin system in COVID-19 induced ARDS and the novel form of medicine--herbal decoctosome from traditional Chinese medicine as effective drugs for COVID-19 treatment. 




The second speaker was Professor Alain Townsend, who is an immunologist and Professor of Molecular Immunology in University of Oxford, Fellow of the Royal Society (FRS) and Fellow of Royal College of Physicians (FRCP).

Professor Townsend brought us the talk “Three COVID-19 Projects: Rapid Affordable Antibody Diagnostic, SpyCatcher-RBD Based Vaccine and Isolation of Neutralising Antibodies”. Professor Townsend introduced in detail the methodology of haemagglutination based antibody diagnostic test, isolation of neutralizing mAbs from SARS-CoV-2 infected convalescent patients, as well as the research on a sub-unit vaccine for COVID-19 that does not require a cold-chain and can be produced rapidly and cheaply.  




In the subsequent Q&A session, the three professors had a lively and pertinent discussion on the protection of the vaccine, the immune escape resulted from the virus mutation, the application prospects and timeline of candidate neutralizing antibodies, and the choice of therapeutic strategies.

At last, Professor Tao Dong expressed her gratitude to both speakers for their fascinating speeches and insightful discussions, and audience for taking time to participate. Our next session will be in early 2021.

Similar stories

Oxford University breakthrough on global COVID-19 vaccine

The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.

COVID Without Borders - A collaboration to Investigate a New Disease II – Vaccine Research and Development

The webinar entitled “COVID Without Borders - A collaboration to Investigate a New Disease II - Vaccine Research and Development” was held online on 22nd September 2020.

COVID Without Borders - A collaboration to Investigate A New Disease

On the morning of 1st July 2020, the webinar “COVID Without Borders – A collaboration to Investigate A New Disease” was held online. It was jointly organised by the Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College and CAMS-Oxford Institute (COI).

COI prioritise funding support to the current crisis caused by novel coronavirus

The CAMS Oxford Institute has prioritised funding support in response to the current crisis caused by nCoV 2019, supporting positive actions taken by the Medical Sciences Divisions and University of Oxford.